MIG-6 Is Critical for Progesterone Responsiveness in Human Complex Atypical Hyperplasia and Early-Stage Endometrial Cancer.
Autorzy:
Jeong O; Department of Obstetrics, Gynecology & Reproductive Biology, College of Human Medicine, Michigan State University, Grand Rapids, MI 49503, USA.; Public Health Sciences Program, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA. BroaddusRR; Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA. Lessey BA; Department of Obstetrics and Gynecology, Atrium Health Wake Forest Baptist, Winston-Salem, NC 27157, USA. Risinger JI; Department of Obstetrics, Gynecology & Reproductive Biology, College of Human Medicine, Michigan State University, Grand Rapids, MI 49503, USA. Hunter MI; Department of Obstetrics, Gynecology and Women's Health, University of Missouri, Columbia, MO 65211, USA. Kim TH; Department of Obstetrics, Gynecology & Reproductive Biology, College of Human Medicine, Michigan State University, Grand Rapids, MI 49503, USA.; Department of Obstetrics, Gynecology and Women's Health, University of Missouri, Columbia, MO 65211, USA.
Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer.
Autorzy:
Bartley AN; From the Department of Pathology, St. Joseph Mercy Hospital, Ann Arbor, Michigan (Bartley). Mills AM; From the Department of Pathology, University of Virginia, Charlottesville (Mills). Konnick E; From the Department of Laboratory Medicine and Pathology, University of Washington, Seattle (Konnick). Overman M; From the Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston (Overman). Ventura CB; From Surveys, College of American Pathologists, Northfield, Illinois (Ventura, Colasacco). Souter L; From Methodology Consultant, Smithville, Ontario, Canada (Souter). Colasacco C; From Surveys, College of American Pathologists, Northfield, Illinois (Ventura, Colasacco). Stadler ZK; From the Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York (Stadler). Kerr S; From Hospital Pathology Associates, PA, Minneapolis, Minnesota (Kerr). Howitt BE; From the Department of Pathology, Stanford University, Stanford, California (Howitt). Hampel H; From the Department of Internal Medicine, The Ohio State University, Columbus (Hampel). Adams SF; From the Department of Obstetrics & Gynecology, University of New Mexico, Albuquerque (Adams). Johnson W; From Fight Colorectal Cancer, Springfield, Missouri (Johnson). Magi-Galluzzi C; From the Department of Pathology, University of Alabama at Birmingham, Birmingham (Magi-Galluzzi). Sepulveda AR; From the Department of Pathology, George Washington University, Washington, District of Columbia (Sepulveda). BroaddusRR; From the Department of Pathology & Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill (Broaddus).
DNA Damage Repair Classifier Defines Distinct Groups in Hepatocellular Carcinoma.
Autorzy:
Smith MA; Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA. Van Alsten SC; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA. Walens A; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. Damrauer JS; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. Maduekwe UN; Department of Surgery, Medical College of Wisconsin, Milwaukee, WI 53226, USA. BroaddusRR; Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. Love MI; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Troester MA; Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599, USA.; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. Hoadley KA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA.; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2022 Sep 01; Vol. 14 (17). Date of Electronic Publication: 2022 Sep 01.
Inactivating Mutations of the IK Gene Weaken Ku80/Ku70-Mediated DNA Repair and Sensitize Endometrial Cancer to Chemotherapy.
Autorzy:
Gao C; Department of Cancer Biology, Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, USA.; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin 300052, China.; Tianjin Key Laboratory of Female Reproductive Health and Eugenics, Tianjin 300052, China. Jin G; Department of Cancer Biology, Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, USA. Forbes E; Department of Cancer Biology, Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, USA. Mangala LS; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.; Center for RNA Interference and Non-Coding RNAs, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. Wang Y; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin 300052, China.; Tianjin Key Laboratory of Female Reproductive Health and Eugenics, Tianjin 300052, China. Rodriguez-Aguayo C; Center for RNA Interference and Non-Coding RNAs, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.; Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. Amero P; Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. Bayraktar E; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.; Center for RNA Interference and Non-Coding RNAs, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. Yan Y; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin 300052, China.; Tianjin Key Laboratory of Female Reproductive Health and Eugenics, Tianjin 300052, China. Lopez-Berestein G; Center for RNA Interference and Non-Coding RNAs, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.; Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. BroaddusRR; Department of Pathology & Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA. Sood AK; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.; Center for RNA Interference and Non-Coding RNAs, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. Xue F; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin 300052, China.; Tianjin Key Laboratory of Female Reproductive Health and Eugenics, Tianjin 300052, China. Zhang W; Department of Cancer Biology, Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, USA.
Pokaż więcej
Źródło:
Cancers [Cancers (Basel)] 2021 May 20; Vol. 13 (10). Date of Electronic Publication: 2021 May 20.
Evaluating Mismatch Repair/Microsatellite Instability Status Using Cytology Effusion Specimens to Determine Eligibility for Immunotherapy.
Autorzy:
Jacobi EM; The Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston.; Jacobi is currently in the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas. Landon G; The Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston. BroaddusRR; The Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston.; Broaddus is currently in the Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill. Roy-Chowdhuri S; The Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston.
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine.
Autorzy:
Tsimberidou AM; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. . Hong DS; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. Wheler JJ; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; Current Address: TScan Therapeutics, Waltham, USA. Falchook GS; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; Current Address: Sarah Cannon Research Institute, Nashville, USA. Janku F; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. Naing A; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. Fu S; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. Piha-Paul S; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. Cartwright C; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. BroaddusRR; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA. Nogueras Gonzalez GM; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA. Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Kurzrock R; Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.; Current Address: Moores Cancer Center-University of California San Diego, San Diego, USA.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2019 Dec 30; Vol. 12 (1), pp. 145. Date of Electronic Publication: 2019 Dec 30.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
G-protein coupled receptor 64 (GPR64) acts as a tumor suppressor in endometrial cancer.
Autorzy:
Ahn JI; Department of Agricultural Biotechnology, Seoul National University, Seoul, 08826, Republic of Korea.; Research Institute of Agriculture and Life Sciences, Seoul National University, Seoul, 08826, Republic of Korea. Yoo JY; Department of Biochemistry and Molecular Biology, Brain Korea 21 PLUS Project for Medical Sciences, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea. Kim TH; Department of Obstetrics and Gynecology & Reproductive Biology, College of Human Medicine, Michigan State University, 400 Monroe Avenue NW, Grand Rapids, MI, 49503, USA. Kim YI; Department of Agricultural Biotechnology, Seoul National University, Seoul, 08826, Republic of Korea.; Research Institute of Agriculture and Life Sciences, Seoul National University, Seoul, 08826, Republic of Korea. BroaddusRR; Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX, 77030, USA. Ahn JY; Department of Agricultural Biotechnology, Seoul National University, Seoul, 08826, Republic of Korea.; Research Institute of Agriculture and Life Sciences, Seoul National University, Seoul, 08826, Republic of Korea. Lim JM; Department of Agricultural Biotechnology, Seoul National University, Seoul, 08826, Republic of Korea. .; Research Institute of Agriculture and Life Sciences, Seoul National University, Seoul, 08826, Republic of Korea. . Jeong JW; Department of Obstetrics and Gynecology & Reproductive Biology, College of Human Medicine, Michigan State University, 400 Monroe Avenue NW, Grand Rapids, MI, 49503, USA. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2019 Aug 14; Vol. 19 (1), pp. 810. Date of Electronic Publication: 2019 Aug 14.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
